Meeting Banner
Abstract #4733

Oxygen-Enhanced MOLLI T1 Mapping during Chemoradiotherapy in Anal Squamous Cell Carcinoma

Emma Bluemke1, Daniel Bulte1, Ambre Bertrand1, Ben George2, Rosie Cooke2, Kwun-Ye Chu3, Lisa Durrant2, Vicky Goh4, Clare Jacobs2, Stasya Ng5, Victoria Strauss6, Maria Hawkins3, and Rebecca Muirhead2
1Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom, 2Department of Oncology, Oxford University Hospitals Trust, Oxford, United Kingdom, 3Radiotherapy Department, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, 4Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, United Kingdom, 5Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom, 6Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom

Early identification of patients in need of radiotherapy treatment intensification would allow tailored radiotherapy dose. We hypothesize that patients with poor vascularity or hypoxia will correlate with these patients, and T1 changes from oxygen-enhanced MRI could provide indications of tumour perfusion. We acquired T1-maps before and after 8-10 fractions of radiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. There was a significant increase in tumour T1 across patients following chemoradiotherapy (p<0.001). Before chemoradiotherapy, OE-MRI showed no significant changes in tumour T1, however after receiving chemoradiotherapy, OE-MRI showed a significant decrease in tumour T1 (p<0.001).

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here